Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price

Lucid Diagnostics (NASDAQ:LUCD) had its price objective increased by Ascendiant Capital Markets from $8.00 to $8.25 in a research note published on Wednesday morning, MarketBeat reports. Ascendiant Capital Markets currently has a buy rating on the stock.

A number of other research analysts also recently commented on the company. Needham & Company LLC reiterated a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday, November 13th. Wall Street Zen downgraded Lucid Diagnostics from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. BTIG Research increased their price target on shares of Lucid Diagnostics from $2.00 to $2.50 and gave the company a “buy” rating in a research note on Friday, September 5th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Lucid Diagnostics in a research report on Monday. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $3.94.

Lucid Diagnostics Stock Up 3.6%

Shares of Lucid Diagnostics stock opened at $1.14 on Wednesday. Lucid Diagnostics has a 52-week low of $0.75 and a 52-week high of $1.80. The company has a market capitalization of $156.96 million, a P/E ratio of -1.10 and a beta of 1.22. The company has a 50 day moving average of $1.12 and a 200 day moving average of $1.14.

Lucid Diagnostics (NASDAQ:LUCD) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.04). The firm had revenue of $1.21 million for the quarter, compared to analyst estimates of $1.35 million. As a group, research analysts anticipate that Lucid Diagnostics will post -0.84 earnings per share for the current fiscal year.

Institutional Trading of Lucid Diagnostics

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE boosted its stake in Lucid Diagnostics by 41.5% during the 3rd quarter. Bank of America Corp DE now owns 40,663 shares of the company’s stock worth $41,000 after purchasing an additional 11,917 shares during the period. Berkshire Asset Management LLC PA purchased a new position in shares of Lucid Diagnostics during the first quarter worth about $30,000. Goldman Sachs Group Inc. increased its position in Lucid Diagnostics by 35.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 86,302 shares of the company’s stock valued at $129,000 after acquiring an additional 22,727 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new stake in Lucid Diagnostics during the 1st quarter valued at approximately $37,000. Finally, Quadrature Capital Ltd acquired a new stake in Lucid Diagnostics during the 2nd quarter worth approximately $29,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.